Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy

Seminars in Nephrology

Volumn 17, Issue 2, 1997, Pages 80-92

  Sharma, Kumar ^a,c   Ziyadeh, Fuad N ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CYTOKINE; ENDOTHELIN; GLUCOSE; MATRIX PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PLATELET DERIVED GROWTH FACTOR; POLYOL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SOMATOMEDIN C; THROMBOXANE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; GLUCOSE METABOLISM; GLYCATION; HYPERGLYCEMIA; KIDNEY HYPERTROPHY; MESANGIUM CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; CYTOKINES; DIABETIC NEPHROPATHIES; GLUCOSE; HUMANS; HYPERGLYCEMIA; KIDNEY; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030898416     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (142)

1. DCCT: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993
2. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
3. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin coverting enzyme-inhibitor benazapril on the progression of chronic renal failure. N Engl J Med 334:939-945, 1996
4. Ziyadeh FN: The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 22:736-744, 1993
5. Wolf G, Sharma K, Chen Y, et al: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF. Kidney Int 42:647-656, 1992
6. Ayo SH, Radnik RA, Garoni J, et al: High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 136:1339-1348, 1990
7. Ayo SH, Radnik R, Garoni JA: High glucose increases diacylglycerol mass and activates protein kinases C in mesangial cell culture. Am J Physiol 261:F571-F577, 1991
8. Ziyadeh FN, Sharma K, Ericksen M, et al: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 93:536-542, 1994
9. Takeuchi A, Throckmorton DC, Brogden AP, et al: Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 268:F13-F19, 1995
10. Heilig C, Concepcion L, Riser B, et al: Overexpression of Glut 1 in rat mesangial cells: A new model to simulate diabetes. J Am Soc Nephrol 5:965, 1994 (abstr)
11. Leehey DJ, Hua Song R, Alavi N, et al: Decreased degradative enzymes in mesangial cells cultured in high glucose media. Diabetes 44:929-935, 1995
12. van den Born J, van Kraats AA, Bakker MAH, et al: Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 38:161-172, 1995
13. van Det NF, van den Born J, Tamsa JT, et al: Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. Kidney Int 49:1079-1089, 1996
14. Kasinath BS, Block JA, Singh AK, et al: Regulation of rat glomerular epithelial cell proteoglycans by high-medium glucose. Arch Biochem Biophys 309:149-159, 1994
15. Goldfarb S, Ziyadeh FN, Kern EFO, et al: Effects of polyol-pathway inhibition and dietary myo-inositol on glo-merularhemodynamic function in experimental diabetes mellitus in rats. Diabetes 40:465-471, 1991
16. DeRubertis FR, Craven PA: Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomemlopathy. Diabetes 43:1-8, 1994
17. Fumo P, Kuncio GS, Ziyadeh FN: PKC and high glucose stimulate collagen alphal (IV) transcriptional activity in a reporter mesangial cell line. Am J Physiol 267:F632-F638, 1994
18. Brownlee M, Vlassara H, Cerami A: Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Int Med 101:527-537, 1984
19. Cohen MP, Hud E, Wu VY: Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin. Kidney Int 45:1673-1679, 1994
20. Rocco MV, Chen Y, Goldfarb S, et al: Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int 41:107-114, 1992
21. Boel E, Selmer J, Flodgaard HJ, et al: Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise? J Diabetes Complications 9:104-129, 1995
22. Pedersen MM, Christiansen JS, Mogensen CE: Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 months of aldose reductase inhibition. Diabetes 40:527-531, 1991
23. Bleyer AJ, Fumo P, Snipes ER, et al: Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule. Kidney Int 45:659-666, 1994
24. Clark CM, Lee DA: Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 332:1210-1217, 1995
25. Williamson JR, Chang K, Frangos M, et al: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813, 1993
26. Cohen AM, Wald H, Popovtzer M, et al: Effect of myo-inositol supplementation on the development of renal pathological changes in the Cohen diabetic (type 2) rat. Diabetologia 38:899-905, 1995
27. Yamaoka T, Nishimura C, Yamshita K, et al: Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 38:255-261, 1995
28. Xia P, Inoguchi T. Kern TS, et al: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hyperglycemia. Diabetes 43:1122-1129, 1994
29. Tilton RG, Baier LD, Harlow JE, et al: Diabetes-induced glomerular dysfunction: Links to a more reduced cytosolic ratio of NADH/NAD+. Kidney Int 41:778-788, 1992
30. Bell RB: Prtotein kinase C activation by diacylglcerol second messengers. Cell 45:631-632, 1986
31. Kreisberg JI, Radnik RA, Ayo SH, et al: High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures. Kidney Int 46:105-112, 1994
32. Sharma K, Danoff TM, DePiero A, et al: Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. Biochem Biophys Res Commun 207:80-88, 1995
33. Kikkawa R, Haneda M, Uzu T, et al: Translocation of protein kinase Ca and z in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia 37:838-841, 1994
34. Inoguchi T, Battan R, Handler E, et al: Preferential elevation of protein kinase C isoform bll and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 89:11059-11063, 1992
35. Ishii H, Jirousek MR, Koya D, et al: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:699-700, 1996
36. Kunisaki M, Bursell SE, Umeda F, et al: Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 43:1372-1377, 1994
37. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46:223-234, 1995
38. Cohen MP, Ziyadeh FN: Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol 7:1-8, 1996
39. Vlassara H: Protein glycation in the kidney. Kidney Int 49:1795-1804, 1996
40. Bucala R, Vlassara H: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 6:875-888, 1995
41. Boyd-White J, Williams JC: Effect of cross-linking on matrix permeability. A model for AGE-modified basement membranes. Diabetes 45:348-353, 1995
42. Kohn RR, Cerami A, Monnier VM: Collagen aging in vitro by nonenzymatic glycosylation and browning. Diabetes 33:57-59, 1984
43. Charonis AS, Tsilbary EC, Yurchenco PD, Furthmayr H: Binding of type IV collagen to laminin. A morphological study. J Cell Biol 100:1848-1853, 1985
44. Anderson SS, Tsilibary EC, Charonis AS: Nonenzymatic glycosylation-induced modifications of intact bovine kidney tubular basement membrane. J CItn Invest 92:3045-3052, 1993
45. Skolnik EY, Yang Z, Makita Z, et al: Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 174:931-939, 1991
46. Brownlee M: The pathological implications of protein glycation. Clin Invest Med 18:275-281, 1995
47. Anderson S, Wu K, Hasegawa G, et al: Effect of glucose/glycation on mesangial cell expression of genes related to the mesangial matrix. J Am Soc Nephrol 5:960, 1994 (abstr)
48. Nishino T, Horii Y, Shiiki H, et al: Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Hum Pathol 26:308-313, 1995
49. Makita Z, Bucala R, Rayfield EJ, et al: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522, 1994
50. Yang CW, Vlassara H, Peten EP, et al: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91:9436-9440, 1994
51. Yang CW, Vlassara H, Striker GE, et al: Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis. Kidney Int 47:S55-S58, 1995
52. Vlassara H, Striker LJ, Teichberg S, et al: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704-11708,1994
53. Brett J, Schmidt AM, Yan SD, et al: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699-1712, 1993
54. Schmidt AM, Mora R, Cao R, et al: The endothelial cell binding site for advanced glycation end products consists of a complex: An integral membrane protein and a lactoferrinlike polypeptide. J Biol Chem 269:9882-9888, 1994
55. Schmidt AM, Hasu M, Popov D, et al: Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 91:8807-8811, 1994
56. Gilcrease MZ, Hoover RL: Human monocyte interactions with non-enzymatically glycated collagen. Diabetologia 35:160-164, 1992
57. Wautier JL, Zoukourian C, Chappey O, et al: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. J Clin Invest 97:238-243, 1996
58. Bischoff H: Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest 3:3-10, 1994
59. Ellis EN, Good BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40:1016-1019, 1991
60. Brownlee M, Vlassara H, Kooney T, et al: Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 232:1629-1632, 1986
61. Chen HJ, Cerami A: Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro. J CarbohydrChem 12:731-742, 1993
62. Yamada H, Miyata S, Igaki N, et al: Increase in 3-deoxyglucosone levels in diabetic rat plasma. J Biol Chem 269:20275-20280, 1994
63. Soulis-Liparota T, Cooper M, Papazoglou D, et al: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
64. Corbett JA, Tilton RG, Chang K, et al: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992
65. Beckerman K, Rogers H, Corbett JA, et al: Release of nitric oxide during the T cell-independent pathway of macrophage activation: Its role in resistance to Listeria monocytogenes. J Immunol 150:888-895, 1993
66. Vasan S, Zhang X, Zhang X, et al: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275-278, 1996
67. McCance DR, Dyer DG, Dunn JA, et al: Maillard reaction products and their relation to complications in insulin dependent diabetes mellitus. J Clin Invest 91:2470-2478, 1993
68. Bunn HF, Gabbay KH, Gallop PM: The glycosylation of hemoglobin: Relevance to diabetes mellitus. Science 200:21-27, 1978
69. Cohen MP, Hud E: Measurement of plasma glycoalbumin levels with a monoclonal antibody based ELSIA. J Immunol Method 122:279-283, 1989
70. Wells-Knecht KJ, Lyons TJ, McChance DR, et al: 3-deoxyglucose concentrations are increased in human plasma and urine in diabetes. Diabetes 43:1152-1156, 1994
71. Cohen MP, Urdanivia E, Surma M, et al: Increase glycosylation of glomerular basement membrane collagen in diabetes. Biochem Biophys Res Commun 95:765-769, 1980
72. Trueb B, Fluckiger R, Winterhalter KH: Non-enzymatic glycosylation of basement membrane collagen in diabetes mellitus. Coll Rel Res 4:239-251, 1984
73. Williams SK, Devenny JJ, Bitensky MW: Micropinocytic ingestion of glycosylated allbumin by isolated microvessels: Possible role in the pathogenesis of diabetic microangiopathy. Proc Natl Acad Sci USA 78:2393-2397, 1981
74. Cohen MP, Hud E, Wu V-Y, et al: Albumin modified by Amadori glucose adducts activates mesangial cell type IV collagen gene transcription. Molec Cell Biochem 151:61-67, 1995
75. 2 production in diabetes: Role of glycated proteins. J Am Soc Nephrol 4:791A, 1993
76. Cohen MP, Ziyadeh FN: Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int 45:475-484, 1994
77. Ziyadeh FN, Cohen MP: Nonenzymatically glycated serum proteins stimulate mesangial cell type IV collagen gene expression. FASEB J 7:A370, 1993 (abstr)
78. Cohen MP: Nonenzymatic glycation and enhanced polyol pathway activity in the pathogenesis of diabetic nephropathy, in Heidland A, Koch KM, Heidbreder E (eds): Diabetes and the Kidney. Karger, Basel, 1989, vol 73, pp 59-72
79. McVerry BA, Hopp A, Fisher C, et al: Production of pseudodiabetic renal glomerular changes in mice after repeated injection of glycosylated proteins. Lancet 2:738-740, 1980
80. Sabbatini M, Sansone G, Uccello F, et al: Early glycosilation products induce glomerular hyperfiltration in normal rats. Kidney Int 42:875-881, 1992
81. Like AA, Lavine RL, Poffenbarger PL, et al: Studies in the diabetic mutant mouse. Am J Pathol 6:193-204, 1972
82. Lee SM, Graham A: Early immunopathologic events in experimental diabetic nephropathy: A study in db/db mice. Exp Mol Pathol 33:323-332, 1980
83. Cohen MP, Hud E, Wu VY, et al: Glycated albumin modified by Amadori adducts modulates aortic endothelial cell biology. Mol Cell Biochem 143:73-79, 1995
84. Wu VY, Cohen MP: Identification of aortic endothelial cell binding proteins for Amadori adducts in glycated albumin. Biochem Biophys Res Commun 193:1131-1136, 1993
85. Wu VY, Cohen MP: Evidence for a ligand receptor system mediating the biologic effects of glycated albumin in glomerular mesangial cells. Biochem Biophys Res Commun 207:521-528, 1995
86. Trachtman H, Futterweit S, Maesaka J, et al: Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats. Am J Physiol 269:F429-F438, 1995
87. van Dam PS, van Asbeck BS, Erkelens DW, et al: The role of oxidative stress in neuropathy and other diabetic complications. Diabetes/Metabolism Rev 11:181-192, 1995
88. Yoshida K, Hirokawa J, Tagami S, et al: Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: Regulation of glutathione synthesis and efflux. Diabetologia 38:201-210, 1995
89. Ha H, Yoon SJ, Kim KH: High glucose can induce lipid peroxidation in the isolated rat glomeruli. Kidney Int 46:1620-1626,1994
90. Craven PA, Caines MA, DeRubertis FR: Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to the hyperfiltration of early diabetes. Metabolism 36:95-103, 1987
91. Craven PA, DeRubertis FR: Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. J Clin Invest 83:1667-1675, 1989
92. Gambardella S, Andreani D, Cancelli A, et al: Renal hemodynamics and urinary excretion of 6-keto prostaglandin F la, and thromboxane B2 in newly diagnosed type I diabetic patients. Diabetes 37:1044-1048, 1988
93. Craven PA, Melhem MF, DeRubertis FR: Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int 42:937-946, 1992
94. DeRubertis FR, Craven PA: Contribution of platelet thromboxane production to enhanced urinary excretion and glomerular production of thromboxane and to the pathogenesis of albuminurira in the streptozotocin-diabetic rat. Metabolism 41:90-96, 1992
95. Bruggeman LA, Horigan EA, Horikoshi S, et al: Thromboxane stimulates synthesis of extracellular matrix proteins in vitro. Am J Physiol 261:F488-F494, 1991
96. Studer RK, Negrete H, Craven PA, et al: Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-beta bioactivity in mesangial cells. Kidney Int 48:422-430, 1995
97. Matsuo Y, Takagawa I, Koshida H, et al: Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis. Pharmacology 50:1-8, 1995
98. Hora K, Oguchi H, Furakawa T, et al: Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy. Nephron 56:297-305, 1990
99. Koide H, Nakamura T, Ebihara I, et al: Endothelins in diabetic kidneys. Kidney Int 48:S45-S49, 1995 (Suppl 51)
100. Morabito E, Corsico N, Arrigoni Martelli E: Endothelins urinary excretion in spontaneously diabetic rats: BB/ BB. Life Sci 56:13-18, 1995
101. Nakamura T, Ebihara I, Fukui M, et al: Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44:895-899, 1995
102. Fukui M, Nakamura T, Ebihara I, et al: Effects of enalapril on endothelin-1 and growth factor expression in diabetic rat glomeruli. J Lab Clin Med 123:763-768, 1994
103. Takahashi K, Ghatei MA, Lam H-C, et al: Elevated plasma endothelin levels in patients with diabetes mellitus. Diabetologia 33:306-310, 1990
104. Morise T, Takeuchi Y, Kawano M, et al: Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 18:87-89, 1995
105. Ferri C, Laurenti O, Bellini C, et al: Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patients. Am J Hypertens 8:40-47, 1995
106. Sharma K, Ziyadeh F: The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 35:F829-F842, 1994
107. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
108. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44:1139-1146, 1995
109. Roberts AB, McCune BK, Sporn MB: TGF-β: Regulation of extracellular matrix. Kidney Int 41:557-559, 1992
110. Heino J, Ignotz RA, Hemler ME, et al: Regulation of cell adhesion receptors by transforming growth factor-β. Concomitant regulation of integrins that share a common b1 subunit. J Biol Chem 264:380-388, 1989
111. Huffman BB, Sharma K, Ericksen M, et al: Transcriptional activation of TGF-β1 by high glucose. J Am Soc Nephrol 6:1041, 1995 (abstrt)
112. Phillips AO, Steadman R, Topley N, et al: Elevated D-glucose concentrations modulate TGF-beta 1 synthesis by human cultured renal proximal tubular cells. The permissive role of platelet-derived growth factor. Am J Pathol 147:362-374, 1995
113. Yamamoto T, Nakamura T, Noble NA, et al: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818, 1993
114. Nakamura T, Fukui M, Ebihara I, et al: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42:450-456, 1993
115. Sharma K, Jin Y, Guo J, et al: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and enhanced extracellular matrix gene expression in streptozotocin-diabetic mice. Diabetes 45:522-530, 1996
116. Pankewycz OG, Guan JX, Bolton WK, et al: Renal TGF-beta regulation in spontaneously diabetic NOD mice with correlations in mesangial cells. Kidney Int 46:748-758, 1994
117. Shankland SJ, Scholey JW: Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int 46:430-442, 1994
118. Yang CW, Hattori M, Vlassara H, et al: Overexpression of transforming growth factor-beta 1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol 5:1610-1617, 1995
119. Iwano M, Kubo A, Nishino T, et al: Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus. Kidney Int 49:1120-1126, 1996
120. Sharma K, McGowan T, Ziyadeh FN, et al: Renal production of TGF-b is increased in diabetic patients. J Am Soc Nephrol 6:455, 1995
121. 120a. Sharma K, Ziyadeh FN, Alzahabi B, et al: Increased renal production of transforming growth factor-β1 but not of endothelin in patients with type II diabetes mellitus. (manuscript in preparation)
122. Serri O, Beauregard H, Brazeau P, et al: Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 265:888-892, 1991
123. Quaife CJ, Mathews LS, Pinkert CA, et al: Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 124:40-48, 1989
124. 2+ mobilization. Biochem Biophys Res Commun 210:378-383, 1995
125. Throckmorton DC, Brogden AP, Min B, et al: PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 48:111-117, 1995
126. Haberstroh U, Zahner G, Disser M, et al: TGF β1 stimulates rat mesangial cell proliferation in culture: Role of PDGF b receptor expression. Am J Physiol 264:F199-F205, 1993
127. Battegay EJ, Raines EW, Seifen RA, et al: TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63:515-524, 1990
128. Zador IZ, Deshmukh GD, Kunkel R, et al: A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J Clin Invest 91:797-803, 1993
129. Negrete H, Studer RK, Craven PA, et al: Role for transforming growth factor-beta in thromboxane-induced increases in mesangial cell fibronectin synthesis. Diabetes 44:335-339, 1995
130. Wolf G, Neilson EG: Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells. Kidney Int 43:S100-S107, 1993
131. Kagami S, Border WA, Miller DE, et al: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437,1994131.
132. Riser BL, Cortes P, Heilig C, et al: Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol 148:1915-1923, 1996
133. Walker JD, Dodds RA, Murrells TJ, et al: Resiliation of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 2:1411-1415, 1989
134. Zeller K, Whittaker E, Sullivan L, et al: Effect of restricting dietary protein on the progression of renal failure in patients with diabetes mellitus. N Engl J Med 324:78-84, 1991
135. Okuda S, Nakamura T, Yamamoto T, et al: Dietary protein restriction rapidly reduces transforming growth factor-β1 expression in experimental glomerulonephritis. Proc Natl Acad Sci USA 88:9765-9769, 1991
136. Eddy AA: Protein restriction reduces transforming growth factor-beta and interstitial fibrosis in nephrotic syndrome. Am J Physiol 266:F884-F893, 1994
137. Border WA, Noble NA, Yamamoto T, et al: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360:361-364, 1992
138. Isaka Y, Brees DK, Ikegaya KO, et al: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 2:418-423, 1996
139. Wolf YG, Rasmussen LM, Ruoslahti E: Antibodies against transforming growth factor-β1 suppress intimai hyperplasia in a rat model. J Clin Invest 93:1172-1178, 1994
140. Takeuchi Y, Kodama Y, Matsumato T: Bone matrix decorin binds transforming growth factor-β and enhances its bioactivity. J Biol Chem 269:32634-32638, 1994
141. Lopez-Casillas F, Payne HM, Andres JL, et al: Betaglycan can act as dual modulator of TGF-beta access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J Cell Biol 124:557-568, 1994
142. O-Connor-McCourt MD, Wakefield LM: Latent transforming growth factor-b in serum: A specific complex with a-2macroglobulin. J Biol Chem 262:14090-14099, 1987